Identification of Novel Target DCTPP1 for Colorectal Cancer Therapy with the Natural Small-molecule Inhibitors Regulating Metabolic Reprogramming

Zhe Wang,Li Feng,Xinjia Wang,Xinrui Guo,Liyuan Shi,Shihuang Su,Xinjing Li,Jia Wang,Ninghua Tan,Yi Ma
DOI: https://doi.org/10.26434/chemrxiv-2024-g54bp
2024-05-08
Abstract:Colorectal cancer (CRC) is one of the most common malignant tumors. Identification of new effective drug targets for CRC and exploration of bioactive small-molecules are clinically urgent. The human dCTP pyrophosphatase 1 (DCTPP1) is a newly identified pyrophosphatase regulating the cellular nucleotide pool but remains unexplored as potential target for CRC treatment. Here, twelve unprecedented chemical architectures terpene-nonadride heterodimers (1–12) and their monomers (13–20) were isolated from endophyte Bipolaris victoriae S27. Compounds 1–12 represented the first example of terpene-nonadride heterodimers, in which nonadride monomers of 1 and 2 were also first example of 5/6 bicyclic nonadrides. A series of assays showed that 2 could repress proliferation and induce cell cycle arrest, apoptotic and autophagic CRC cell death in vitro and in vivo. Clinical cancer samples data revealed that DCTPP1 was a novel target associated with poor survival in CRC. DCTPP1 was also identified as a new target protein of 2. Mechanistically, compound 2 bound to DCTPP1, inhibited its enzymatic activity, intervened with amino acid metabolic reprogramming, and exerted anti-CRC activity. Our study demonstrates that DCTPP1 was a novel potential biomarker and therapeutic target in CRC, and 2 was the first natural anti-CRC drug candidate targeting DCTPP1.
Chemistry
What problem does this paper attempt to address?
The paper attempts to address the issue of identifying new therapeutic targets for colorectal cancer (CRC) and exploring the role of bioactive small molecules in regulating metabolic reprogramming. Specifically, the study aims to: 1. **Identify new drug targets**: The paper focuses on human dCTP pyrophosphatase 1 (DCTPP1), a newly discovered pyrophosphatase that can regulate the cellular nucleotide pool. Although DCTPP1 is closely related to tumor development and progression, its potential as a therapeutic target for CRC has not been fully explored. 2. **Explore bioactive small molecules**: Twelve previously unseen terpene-nonadride heterodimers and their monomers were isolated from the plant endophytic fungus Bipolaris victoriae S27, and these compounds were evaluated for their inhibitory effects on CRC. 3. **Validate potential mechanisms**: Through a series of experiments, including the detection of cell proliferation, cell cycle arrest, apoptosis, and autophagy, as well as the analysis of clinical sample data, the inhibitory effect of compound 2 on DCTPP1 and its impact on amino acid metabolic reprogramming were validated. 4. **Evaluate pharmacokinetic properties**: The pharmacokinetic properties of compound 2 were evaluated in Sprague-Dawley rats to determine its feasibility as a potential drug candidate. Overall, the study aims to provide new strategies for the treatment of CRC by identifying DCTPP1 as a new therapeutic target and developing natural small molecule inhibitors targeting this target.